J COMP EFFECT RES 润色咨询

Journal of Comparative Effectiveness Research

出版年份：暂无数据 年文章数：633 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：16.9% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2194571, encodeId=7e5a21945e1f6, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：版面费多少？审稿久吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae149164058, createdName=ms4000001835740066, createdTime=Thu Mar 21 21:49:57 CST 2024, time=2024-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192291, encodeId=309e119229188, content=请问这个杂志临床文章要提供临床试验注册吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e56499071, createdName=ms7000001349104673, createdTime=Fri Feb 11 12:36:01 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105865, encodeId=cfad110586578, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105866, encodeId=1d62110586669, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846180, encodeId=3e0f8461800c, content=这个期刊还不错，最近几年if一直在涨，审稿人也很热心，提的意见都很棒。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b62f5414001, createdName=ms391324488810565, createdTime=Mon Aug 13 15:58:34 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2024-03-21 ms4000001835740066 来自广东省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：癌症
    经验分享：版面费多少？审稿久吗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2194571, encodeId=7e5a21945e1f6, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：版面费多少？审稿久吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae149164058, createdName=ms4000001835740066, createdTime=Thu Mar 21 21:49:57 CST 2024, time=2024-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192291, encodeId=309e119229188, content=请问这个杂志临床文章要提供临床试验注册吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e56499071, createdName=ms7000001349104673, createdTime=Fri Feb 11 12:36:01 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105865, encodeId=cfad110586578, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105866, encodeId=1d62110586669, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846180, encodeId=3e0f8461800c, content=这个期刊还不错，最近几年if一直在涨，审稿人也很热心，提的意见都很棒。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b62f5414001, createdName=ms391324488810565, createdTime=Mon Aug 13 15:58:34 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2022-02-11 ms7000001349104673

    请问这个杂志临床文章要提供临床试验注册吗

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2194571, encodeId=7e5a21945e1f6, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：版面费多少？审稿久吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae149164058, createdName=ms4000001835740066, createdTime=Thu Mar 21 21:49:57 CST 2024, time=2024-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192291, encodeId=309e119229188, content=请问这个杂志临床文章要提供临床试验注册吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e56499071, createdName=ms7000001349104673, createdTime=Fri Feb 11 12:36:01 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105865, encodeId=cfad110586578, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105866, encodeId=1d62110586669, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846180, encodeId=3e0f8461800c, content=这个期刊还不错，最近几年if一直在涨，审稿人也很热心，提的意见都很棒。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b62f5414001, createdName=ms391324488810565, createdTime=Mon Aug 13 15:58:34 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2021-12-29 Gym璨烨

    如何判断两种药物之间是协同作用还是相加作用？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2194571, encodeId=7e5a21945e1f6, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：版面费多少？审稿久吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae149164058, createdName=ms4000001835740066, createdTime=Thu Mar 21 21:49:57 CST 2024, time=2024-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192291, encodeId=309e119229188, content=请问这个杂志临床文章要提供临床试验注册吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e56499071, createdName=ms7000001349104673, createdTime=Fri Feb 11 12:36:01 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105865, encodeId=cfad110586578, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105866, encodeId=1d62110586669, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846180, encodeId=3e0f8461800c, content=这个期刊还不错，最近几年if一直在涨，审稿人也很热心，提的意见都很棒。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b62f5414001, createdName=ms391324488810565, createdTime=Mon Aug 13 15:58:34 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2021-12-29 Mia

    如果文章发表了未提供ORCIDID如何添加？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2194571, encodeId=7e5a21945e1f6, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：版面费多少？审稿久吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae149164058, createdName=ms4000001835740066, createdTime=Thu Mar 21 21:49:57 CST 2024, time=2024-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192291, encodeId=309e119229188, content=请问这个杂志临床文章要提供临床试验注册吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06e56499071, createdName=ms7000001349104673, createdTime=Fri Feb 11 12:36:01 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105865, encodeId=cfad110586578, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105866, encodeId=1d62110586669, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846180, encodeId=3e0f8461800c, content=这个期刊还不错，最近几年if一直在涨，审稿人也很热心，提的意见都很棒。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b62f5414001, createdName=ms391324488810565, createdTime=Mon Aug 13 15:58:34 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 ms391324488810565

    这个期刊还不错，最近几年if一直在涨，审稿人也很热心，提的意见都很棒。

    0

共9条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分